In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.
Publication
, Journal Article
Miller, JL; Schell, WA; Wills, EA; Toffaletti, DL; Boyce, M; Benjamin, DK; Bartroli, J; Perfect, JR
Published in: Antimicrob Agents Chemother
February 2004
The activity of albaconazole (UR-9825; J. Uriach & Cía. S.A., Barcelona, Spain) was compared to that of fluconazole against 12 isolates of Cryptococcus neoformans in vitro and against 1 isolate in vivo in a rabbit model of cryptococcal meningitis. Albaconazole was 100-fold more potent in vitro than fluconazole on a per-weight basis and was fungicidal at potentially relevant concentrations for two isolates. MICs ranged from
Duke Scholars
Published In
Antimicrob Agents Chemother
DOI
ISSN
0066-4804
Publication Date
February 2004
Volume
48
Issue
2
Start / End Page
384 / 387
Location
United States
Related Subject Headings
- Triazoles
- Survival Analysis
- Rabbits
- Quinazolines
- Microbiology
- Microbial Sensitivity Tests
- Meningitis, Cryptococcal
- Fluconazole
- Cryptococcus neoformans
- Colony Count, Microbial
Citation
APA
Chicago
ICMJE
MLA
NLM
Miller, J. L., Schell, W. A., Wills, E. A., Toffaletti, D. L., Boyce, M., Benjamin, D. K., … Perfect, J. R. (2004). In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother, 48(2), 384–387. https://doi.org/10.1128/AAC.48.2.384-387.2004
Miller, J. L., W. A. Schell, E. A. Wills, D. L. Toffaletti, M. Boyce, D. K. Benjamin, J. Bartroli, and J. R. Perfect. “In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.” Antimicrob Agents Chemother 48, no. 2 (February 2004): 384–87. https://doi.org/10.1128/AAC.48.2.384-387.2004.
Miller JL, Schell WA, Wills EA, Toffaletti DL, Boyce M, Benjamin DK, et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother. 2004 Feb;48(2):384–7.
Miller, J. L., et al. “In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.” Antimicrob Agents Chemother, vol. 48, no. 2, Feb. 2004, pp. 384–87. Pubmed, doi:10.1128/AAC.48.2.384-387.2004.
Miller JL, Schell WA, Wills EA, Toffaletti DL, Boyce M, Benjamin DK, Bartroli J, Perfect JR. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother. 2004 Feb;48(2):384–387.
Published In
Antimicrob Agents Chemother
DOI
ISSN
0066-4804
Publication Date
February 2004
Volume
48
Issue
2
Start / End Page
384 / 387
Location
United States
Related Subject Headings
- Triazoles
- Survival Analysis
- Rabbits
- Quinazolines
- Microbiology
- Microbial Sensitivity Tests
- Meningitis, Cryptococcal
- Fluconazole
- Cryptococcus neoformans
- Colony Count, Microbial